The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...

Cancer immunotherapy has historically focused on harnessing the ability of T cells to recognize and attack cancer cells. Adaptive immune checkpoint inhibitors (ICIs) unleash tumor-infiltrating ...

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 ...

PD-1 and PD-L1 inhibitors are types of immune checkpoint inhibitors, which are immunotherapy medications for treating cancer. Immunotherapy helps the immune system find and kill cancer cells. Some ...

Please provide your email address to receive an email when new articles are posted on . Current therapies do not prevent the onset of new lesions within a field of cancerization. Immune checkpoint ...

A tumor “don’t‑eat‑me” shield also hides pro‑immune danger signals; new antibodies that unmask this hidden cue could make cancers more vulnerable to immune attack.

Feasibility Study for Using Large Language Models to Identify Goals-of-Care Documentation at Scale in Patients With Advanced Cancer A retrospective analysis of 3,626 patients treated with ICIs for ...

Candel Therapeutics (CADL) stock rises as the company updates results from an ongoing mid-stage trial for its lead candidate, CAN-2409 in lung cancer. Read more here.

Please provide your email address to receive an email when new articles are posted on . An analysis of patients treated with immune checkpoint inhibitors for NSCLC showed a significantly lower ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...